Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) CFO Matt Abernethy sold 14,100 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total value of $2,120,358.00. Following the sale, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at $4,741,180.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Neurocrine Biosciences Price Performance
NBIX opened at $145.01 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $103.63 and a 1-year high of $157.98. The stock’s 50 day simple moving average is $141.96 and its 200 day simple moving average is $138.94. The stock has a market cap of $14.59 billion, a P/E ratio of 39.95 and a beta of 0.37.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company had revenue of $590.20 million during the quarter, compared to analysts’ expectations of $545.98 million. During the same period in the previous year, the company posted $0.95 EPS. Neurocrine Biosciences’s quarterly revenue was up 30.4% compared to the same quarter last year. Research analysts expect that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Neurocrine Biosciences
Wall Street Analyst Weigh In
Several analysts have commented on NBIX shares. BMO Capital Markets upped their price objective on Neurocrine Biosciences from $129.00 to $138.00 and gave the company a “market perform” rating in a research note on Thursday, May 2nd. UBS Group upped their price objective on Neurocrine Biosciences from $174.00 to $193.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. Evercore ISI started coverage on Neurocrine Biosciences in a research note on Tuesday, May 14th. They set an “outperform” rating and a $175.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Finally, Guggenheim boosted their target price on Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences has an average rating of “Moderate Buy” and a consensus target price of $158.68.
View Our Latest Report on NBIX
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Articles
- Five stocks we like better than Neurocrine Biosciences
- What is Put Option Volume?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 8/12 – 8/16
- Canada Bond Market Holiday: How to Invest and Trade
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.